Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

por Lu, Xiaoyan, Smare, Caitlin, Kambili, Chrispin, El Khoury, Antoine C., Wolfson, Lara J.
Publicado 2017

Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK

por Wolfson, Lara J., Walker, Anna, Hettle, Robert, Lu, Xiaoyan, Kambili, Chrispin, Murungi, Andrew, Knerer, Gerhart
Publicado 2015

Population Pharmacokinetic Analysis of Bedaquiline‐Clarithromycin for Dose Selection Against Pulmonary Nontuberculous Mycobacteria Based on a Phase 1, Randomized, Pharmacokinetic S...

por Kurosawa, Ken, Rossenu, Stefaan, Biewenga, Jeike, Ouwerkerk‐Mahadevan, Sivi, Willems, Wouter, Ernault, Etienne, Kambili, Chrispin
Publicado 2021

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China

por Agnarson, Abela Mpobela, Wang, Xiao Chun, Potluri, Ravi, Bhandari, Hitesh, Dhir, Amit, Kambili, Chrispin, Metz, Laurent
Publicado 2020

Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial

por Meyvisch, Paul, Kambili, Chrispin, Andries, Koen, Lounis, Nacer, Theeuwes, Myriam, Dannemann, Brian, Vandebosch, An, Van der Elst, Wim, Molenberghs, Geert, Alonso, Ariel
Publicado 2018